XML 45 R32.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
SEGMENTED INFORMATION
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Segment Reporting [Abstract]    
SEGMENTED INFORMATION [Text Block]

17. SEGMENTED INFORMATION

The Company reports its financial results for the following two operating segments, which are also its reportable segments: commercial and wholesale (primarily FGH subsidiaries) and house of brands (primarily JustCBD and Vessel subsidiaries). These segments reflect how the Company's operations are managed, how the Company Chief Executive Officer, who is the chief operating decision maker, allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured.

For the year ended December 31, 2023, the Company had three operating segments, which were also its reportable segments: commercial and wholesale, house of brands and pharmaceuticals (formerly the Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries in Colombia). Due to the sale of the Colombian subsidiaries during 2023 and the resulting reclassification into discontinued operations, the Company no longer reports a pharmaceuticals segment.  

The Company's operates its manufacturing and distribution business within its United States and Germany subsidiaries. Management has defined the reportable segments of the Company based on this internal business unit reporting, which is by major product line, and aggregates similar businesses into the house of brands segment below. The Corporate segment reflects balances and expenses that do not directly influence business unit operations and includes the Company's long-term investments.

Information regarding the Company's segments is summarized as follows:

   

For the three

months ended

    

For the three

months ended

  
    March 31, 2024     March 31, 2023  
Net Sales            
Commercial & Wholesale $ 11,342   $ 7,958  
House of Brands   8,020     13,765  
Eliminations   (1,331 )   (2,404 )
  $ 18,031   $ 19,319  
             
Net (Loss) Income from Continuing Operations            
Commercial & Wholesale $ (236 ) $ 140  
House of Brands   (967 )   (354 )
Corp & Eliminations   (2,171 )   (2,972 )
  $ (3,374 ) $ (3,186 )

 

As at   March 31, 2024     December 31, 2023  
Assets            
Commercial & Wholesale $ 10,473   $ 9,096  
House of Brands   11,377     11,608  
Corp & Eliminations   2,424     2,922  
  $ 24,274   $ 23,626  

Disaggregation of net sales by geographic area:

   

For the three

months ended

    

For the three

months ended

  
    March 31, 2024     March 31, 2023  
Net Sales            
United States $ 6,518   $ 10,999  
Germany   11,343     7,958  
United Kingdom   170     362  
  $ 18,031   $ 19,319  

24. SEGMENTED INFORMATION

Prior to the fourth quarter of the year ended December 31, 2022, the Company had the following four operating segments, which were also its reportable segments: cannabis growth and derivative production, consumer products, pharmaceuticals and nutraceuticals, and beverage and food. Since the acquisition of FGH in December 2022 (Note 10), the Company has been reporting its financial results for the following three operating segments, which are also its reportable segments: commercial and wholesale (primarily FGH and the former Cosechemos subsidiary in Colombia), house of brands (primarily JustCBD and Vessel, as well as the former Kasa Wholefoods Company subsidiary in Colombia), and pharmaceuticals (formerly the Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries in Colombia). These segments reflect how the Company's operations are managed, how the Company Chief Executive Officer, who is the chief operating decision maker, allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured.

As discussed in Note 2 and Note 5, on July 5, 2023, the Company entered into a Share Purchase Agreement with Lisan to sell all its shares in its Colombian related subsidiaries and its Colombian assets. This sale was completed in full on November 1, 2023. As such, the Company has presented the associated assets and liabilities of these Colombian subsidiaries as held for sale and the results of these subsidiaries are included in discontinued operations.

The Company's operates its manufacturing and distribution business within its United States and Germany subsidiaries. Management has defined the reportable segments of the Company based on this internal business unit reporting, which is by major product line, and aggregates similar businesses into the house of brands segment below. The Corporate segment reflects balances and expenses that do not directly influence business unit operations and includes the Company's long-term investments.

The following tables show information regarding the Company's segments for the years ended December 31, 2023 and 2022.

In 2023, the Company did not have sales to a single customer exceeding 10% of its consolidated revenue. In 2022, the Company did not have sales to a single customer exceeding 10% of its consolidated revenue.

    December 31, 2023     December 31, 2022  
Net Sales            
Commercial & Wholesale $ 38,262   $ 87  
House of Brands   44,602     39,419  
Pharmaceuticals   -     -  
Eliminations   (6,793 )   (6,105 )
  $ 76,071   $ 33,401  
             
Gross Profit            
Commercial & Wholesale $ 2,218   $ (39 )
House of Brands   15,520     13,290  
Pharmaceuticals   -     -  
Corp & Eliminations   -     -  
  $ 17,738   $ 13,251  
             
Net Loss from Continuing Operations            
Commercial & Wholesale $ (8,763 ) $ (109 )
House of Brands   (31,399 )   (29,594 )
Pharmaceuticals   (81 )   -  
Corp & Eliminations   (6,426 )   (17,000 )
  $ (46,669 ) $ (46,703 )

Other significant items:

    Commercial &
Wholesale		     House of
Brands		     Pharmaceuticals     Corporate &
Eliminations		     Consolidated  
2023                              
Stock based compensation $ -   $ -   $ -   $ 1,591   $ 1,591  
Interest expense (income)   93     11     -     (12 )   92  
Income taxes   (1,650 )   3     -     19     (1,628 )
Depreciation and amortization   857     1,478     -     -     2,335  
Unrealized gain from changes in fair value   -     (964 )   -     (1,027 )   (1,991 )
Total assets   9,096     11,608     -     2,922     23,626  
                               
2022                              
Stock based compensation $ -   $ -   $ -   $ 3,404   $ 3,404  
Interest expense (income)   1     (27 )   -     (3 )   (29 )
Income taxes   (12 )   (1,393 )   -     -     (1,405 )
Depreciation and amortization   1     2,077     -     66     2,144  
Unrealized loss from changes in fair value   -     -     -     593     593  
Total assets   22,225     48,950     3,313     6,499     80,987  

Disaggregation of net sales and net loss before income taxes by geographic area:

    December 31, 2023     December 31, 2022  
Net Sales            
United States $ 36,536   $ 32,312  
Germany   38,262     87  
United Kingdom   1,273     1,002  
  $ 76,071   $ 33,401  
 
    December 31, 2023     December 31, 2022  
Net Loss Before Income Taxes            
United States $ (31,013 ) $ (27,867 )
Germany   (10,258 )   (121 )
United Kingdom   (364 )   (3,120 )
Canada   (6,662 )   (17,000 )
  $ (48,297 ) $ (48,108 )

Disaggregation of property, plant and equipment and other long-lived assets by geographic area:

    December 31, 2023     December 31, 2022  
Property, Plant and Equipment            
United States $ 354   $ 759  
Germany   493     459  
  $ 847   $ 1,218  
    December 31, 2023     December 31, 2022  
Other Long-lived Assets            
United States $ 1,140   $ 33,332  
Germany   -     9,969  
Colombia   -     4,392  
United Kingdom   89     191  
Canada   186     730  
  $ 1,415   $ 48,614  
 
    December 31, 2023     December 31, 2022  
Total Assets            
United States $ 11,094   $ 45,341  
Germany   9,096     19,382  
Colombia   -     8,122  
United Kingdom   514     559  
Canada   2,922     7,583  
  $ 23,626   $ 80,987